Indian Journal of Clinical Biochemistry

, Volume 29, Issue 1, pp 69–73 | Cite as

Effect of Resveratrol and Nicotine on PON1 Gene Expression: In Vitro Study

  • Nidhi Gupta
  • Ramesh Kandimalla
  • Kumari Priyanka
  • Gagandip Singh
  • Kiran Dip Gill
  • Surjit SinghEmail author
Original Article


Dietary and lifestyle factors have been shown to have a profound effect on paraoxonase-1 (PON1) activity. Cigarette smoke has been shown to inhibit its mass and activity where as resveratrol has been shown to enhance it. We exposed hepatoma derived cell line (HepG2) to resveratrol and nicotine in varying doses and measured PON1 enzymatic activity and PON1 gene expression. In addition, total protein content of HepG2 cells was also measured. Resveratrol in a dose of 15 μmol/l or above significantly increased the PON1 enzyme activity (p > 0.001) where as nicotine in a dose of 1 μmol/l or higher significantly reduced it (p < 0.05). The resveratrol in this dose also enhanced the PON1 gene expression whereas nicotine decreased it as compared to controls. However, the protein conent of cells was not changed suggesting that they were not cytotoxic in the doses used. Till date the antioxidant vitamins have shown disappointing results against LDL oxidation and cardiovascular protection. However, the effect of resveratrol on PON1 gene expression and activity was significant, suggesting increase in PON1 activity and enhanced gene expression may be its alternative mechanism for offering protection against cardiovascular disease and may be an potential pharmacological agent which can be used for this.


Paraoxonase1 PON1 gene expression HepG2 cell line Resveratrol Nicotine 


  1. 1.
    Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–24.PubMedCrossRefGoogle Scholar
  2. 2.
    Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441–7.PubMedCrossRefGoogle Scholar
  4. 4.
    James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 2000;101:2252–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem Biophys Res Commun. 1997;236:289–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Aviram M, Fuhrman B. Wine flavonoids protect against LDL oxidation and atherosclerosis. Ann N Y Acad Sci. 2002;957:146–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003;17:197501985.CrossRefGoogle Scholar
  8. 8.
    Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, aphytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73:1393–400.PubMedCrossRefGoogle Scholar
  9. 9.
    Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, et al. Resveratrol scavenges reactive oxygen species and effects radical induced cellular responses. Biochem Biophys Res Commun. 2003;309:1017–26.PubMedCrossRefGoogle Scholar
  10. 10.
    Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol. 2000;59:865–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms haplotypes and activity in predicting CAD risk in North-West Indian Punjabis. PLoS ONE. 2011;6:e17805.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21:1451–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Frankel EM, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet. 1993;341:1103–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36:79–87.PubMedCrossRefGoogle Scholar
  16. 16.
    Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res. 1998;24:133–8.PubMedGoogle Scholar
  17. 17.
    Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb VascBiol. 2002;22:1248–50.CrossRefGoogle Scholar
  18. 18.
    Leiro J, Arranz JA, Fraiz N, Sanmartin ML, Quezada E, Orallo F. Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol. 2005;5:393–406.PubMedCrossRefGoogle Scholar
  19. 19.
    Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z. Resveratrol attenuates TNF alpha induced activation of coronary arterial endothelial cells: role of NF-kappa B inhibition. Am J Physiol Heart Circ Physiol. 2006;291:H1694–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Zbikowska HM, Olas B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51:513–20.PubMedGoogle Scholar
  21. 21.
    De Biase L, Pignatelli P, Lenti L, Tocci G, Piccioni F, Riondino S, et al. Enhanced TNF alpha and oxidative stress in patients with heart failure: effect of TNF alpha on platelet O2-production. Thromb Haemost. 2003;90:317–25.PubMedGoogle Scholar
  22. 22.
    Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of reveratrol. Carcinogenesis. 2001;22:1111–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000;141:3657–67.PubMedGoogle Scholar
  24. 24.
    Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase1 gene expressionby an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol. 2004;24:5209–22.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2013

Authors and Affiliations

  • Nidhi Gupta
    • 1
  • Ramesh Kandimalla
    • 1
  • Kumari Priyanka
    • 1
  • Gagandip Singh
    • 2
  • Kiran Dip Gill
    • 1
  • Surjit Singh
    • 3
    Email author
  1. 1.Department of BiochemistryPostgraduate Institute of Medical Education and Research, Nehru HospitalChandigarhIndia
  2. 2.Department of CardiologyPostgraduate Institute of Medical Education and Research, Nehru HospitalChandigarhIndia
  3. 3.Department of Internal MedicinePostgraduate Institute of Medical Education and Research, Nehru HospitalChandigarhIndia

Personalised recommendations